Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.

TL;DR: The mechanism of action of trastuzumab emtansine, the key clinical results obtained with it, the combinations of T- DM1 with other cytotoxic agents and anti-HER drugs, and the potential resistance mechanisms and the strategies to overcome resistance to T-DM1 are discussed.

TL;DR: The key parameters for designing a powerful ADC are reviewed, focusing on how ADCs are addressing the challenge of multiple drug resistance (MDR) and its rational overcoming.

TL;DR: Pertuzumab and T-DM1 are a humanized monoclonal antibody that binds to the extracellular portion of the receptor on a domain distinct from the binding site of trastuzumAB that results in synergistic tumor cell inhibition and has been shown to significantly improve clinical outcomes for patients with HER2-positive metastatic breast cancer.

TL;DR: In this article, the authors evaluated levels of sHER2 during treatment and at the time of disease recurrence in the adjuvant North Central Cancer Treatment Group N9831 clinical trial.